Korro secures approvals in Australia to commence AATD trial of KRRO-110
Korro Bio has secured approvals in Australia to commence the two-part Phase I/IIa REWRITE trial of its investigational product, KRRO-110, …
Post
-
-
Patient dies in Neurogene’s Phase I/II Rett syndrome trial
A patient taking part in Neurogene’s Rett syndrome trial has died following complications from a rare hyperinflammatory syndrome associated with …
-
Humacyte sees success in dual emergency-engineered tissue trials
Humacyte’s acellular tissue-engineered vessel (ATEV), designed for use in extreme situations where civilians or soldiers have been injured, is better …
-
Rallybio commences Phase II trial of RLYB212 for FNAIT in pregnant women
Rallybio has commenced an open-label Phase II trial of RLYB212 in pregnant women at higher risk for HPA-1a alloimmunisation and …
-
ImmunityBio and nCartes partner to automate clinical trial data processes
ImmunityBio has partnered with nCartes to automate and expedite the data fulfilment process for clinical trials, aiming to transform the …
-
Neuralink receives Health Canada approval to launch trial of implantable device
Neuralink has received approval from Health Canada to launch the first global trial, ‘Canadian Precise Robotically Implanted Brain-Computer Interface’ (CAN-PRIME), …
-
Leading sales enablement, prospecting and automation providers and technology solutions for the clinical trials industry
Leading sales enablement, prospecting and automation providers and technology solutions for the clinical trials industry: Introduction In the rapidly evolving landscape …
-
Dr Oz nominated to lead CMS despite big pharma ties
Television personality Dr Mehmet Oz has been nominated by President-elect Donald Trump Jr to lead the Centers for Medicare and …
-
How APIs can unlock automation and efficiencies across eClinical technologies
Clinical trials have always been complex, but the last five to ten years have seen an increase in complexities due …
-
Daiichi Sankyo exec on purposeful data collection
Daiichi Sankyo’s VP of digital excellence, Dr Patrick Markt-Niederreiter , has outlined how the pharma company makes ‘very conscious’ decisions …
-
Endeavor doses first subject in Phase IIb trial of ENV-101 for IPF treatment
Endeavor BioMedicines has dosed the first subject in the randomised Phase IIb WHISTLE-PF trial in Australia, assessing the efficacy and …
-
Worldwide 2024 elections pose pivotal shifts in life sciences and healthcare
The outcomes of this year’s US, EU, and UK elections and their downstream effects will lead to drastic changes to …
-
Sage ends dalzanemdor development following Phase II trial failure
Sage Therapeutics announced yesterday (20 November) that its Phase II DIMENSION study for dalzanemdor (SAGE-718) failed to meet its primary …
-
Bayer expands indications for Nubeqa with new drug application
TheUS Food and Drug Administration (FDA) has accepted Bayer’s supplemental new drug application (sNDA) for its oral androgen receptor inhibitor …
-
New Amsterdam sees success in Phase III cardiovascular disease trial
Dutch late-stage clinical biopharma company, New Amsterdam, has unveiled positive topline data from the company’s Phase III TANDEM trial examining …
